GLPG1690 is the latest offering from Belgium-based clinical biotechnology company, Galapagos NV, which has pioneered novel approaches toward treating pulmonary and inflammatory diseases.

How GLPG1690 Works

GLPG1690 is unique in that it targets a novel molecule, GPR84, a pro-inflammatory protein responsible for chronic low grade inflammatory diseases. The mechanism of action was proven in a Phase 1 clinical trial conducted by the company, which yielded positive results in terms of efficacy, safety, and tolerability.

The study was a randomized, double-blind, placebo-controlled, single-center study conducted in 40 healthy volunteers in Belgium, with escalating oral doses. The first part of the study included single ascending doses and the second part involved administration of daily doses for 14 days.

Next Steps for GLPG1690

With favorable pharmacokinetic and pharmacodynamic properties of the drug, along with proper engagement with the target molecule evaluated with the help of a biomarker, Galapagos decided to proceed with a Phase 2 clinical trial to test the effectiveness of this oral formulation in patients with idiopathic pulmonary fibrosis (IPF).

In April 2016, Galapagos announced it started a Phase 2a study with GLPG1690 in IPF patients. The FLORA clinical trial is a randomized, double-blind, placebo-controlled study investigating a once-daily oral dose of GLPG1690 administered for 12 weeks in 24 patients. The primary endpoints are to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug candidate.

Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. 

Sign Up for the Latest GLPG1690 News:

Your Name (required)

Your Email (required)

One comment

  1. Perry says:

    Dear sir/madam,

    The information regarding GLPG1690 is not correct/complete.

    The target is not GPR84. This classifies for GLPG1205, which is also being investigated for IPF. Start op phase 2 later in 2018.

    GLPG1690 is an first-in-class autotaxin (ATX) inhibitor.

    Maybe it’s good to mention the result of the phase 2 study of GLPG1690 FLORA study.

    “GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial. Forced vital capacity (FVC) in lungs stabilized over the 12-week treatment period”

    In April 2018, Galapagos announced the design of a worldwide Phase 3 program to evaluate GLPG1690 in patients with idiopathic pulmonary fibrosis. The planned ISABELA Phase 3 program with GLPG1690 is intended to support both New Drug Application (NDA) and Market Authorization Application (MAA) submissions in respectively the US and EU. It is expected that the ISABELA studies sponsored by Galapagos will start in the 2nd half of 2018.

    GLPG1690 is fully proprietary to Galapagos and has been granted orphan status in Europe and the US.

    Preliminary information about the ISABELA studies to be found at

    I think this is important to notice on the website.

    Thanks for your attention.

    With regards

Leave a Comment

Your email address will not be published. Required fields are marked *